Tracers / [177Lu]Lu-girentuximab
[177Lu]Lu-girentuximab
Also written as [Lu-177]Lu-girentuximab
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- Anti-CA-IX monoclonal antibody (DOTA-conjugated girentuximab)
- Target / mechanism
- Carbonic Anhydrase IX (CA-IX) PMID 40227816
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >95% | >95% | DOTA-Girentuximab | 41631002 2026 Gastro Hep Adv [177Lu]LuCl3 (900 MBq) in HCl (110 μL, 0.05 M) was neutralized with ammonium acetate solution (1 M, pH 6–7) then DOTA-Girentuximab (1.8 mg) was added. — Aliquot was analyzed and found to have a radiochemical yield of >95% with >95% radiochemical purity. |
| Manual synthesis | — | — | — | — | DOTA-girentuximab EndolucinBeta™/ITG, Garching, Germany | 40227816 2025 Cancers (Basel) DOTA-girentuximab was radiolabeled with lutetium-177 to reach 1000 MBq/mg final specific activity and 800 MBq/mL final concentration |
Need this precursor?We can point you to suppliers for [177Lu]Lu-girentuximab, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41631002: 'DOTA-Girentuximab'.